drugset

drugset / Trial / NCT02469688

A Study of ASP4070 to Confirm Safety and Immunological Response in Patients With Pollen Allergy

NCT02469688 ↗

Phase 1 Completed 66 enrolled Astellas Pharma Inc Immunomic Therapeutics, Inc. · collab

RandomizedParallel-groupQuadruple-blindPrevention

Summary

Examine safety and immunological response for ASP4070 when vaccinated in patients with pollen allergy

Timeline

Start: 2015-06-18
Primary completion: 2015-11-27
Completion: 2016-07-26

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ASP4070	Vaccine	—	Intramuscular

Indications